About
Science
Publications
Team
News
Careers
Contact us
inWhite
tw_white-black
MoreMenu
CloseWhite
About
Science
Publications
Team
News
Careers
Contact us
inWhite
tw_white-black
News
Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
Asgard Therapeutics to present positive in vivo efficacy data with AT-108 as monotherapy at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Asgard Therapeutics Strengthens Scientific Advisory Board with Two Appointments
Asgard Therapeutics announces publication on direct reprogramming of cancer cells to force antigen presentation, in collaboration with Lund University
Asgard Therapeutics highlighted at the Medicon Valley Alliance/ Øresundsinstituttet report
Posted 26 December, 2020